Cumulative data suggest depression in adulthood being connected to reduced availability of brain serotonin while the role of dopamine remains less specific. Prospective studies have shown a continuity of depressive episodes from childhood to adulthood, combined with poor social function and excess mortality. The object of this study was to examine whether alterations in brain serotonin and/or dopamine transporter levels are already present in depressive children and adolescents. We examined 41 drug-naive patients (aged 7-17) by single photon emission tomography (SPET) using iodine-123-labelled 2␤-carbomethoxy-3␤(iodophenyl) tropane [
Introduction
The current hypothesis regarding the cause of depressive illness in adults is based on findings of a deficiency of available serotonin in the brain. 1 Striatal dopamine is thought to draw attention to the rewarding stimuli, presumably those of pleasure. 2 Experimental dopamine deficiency detracts from motor function, initiative and happiness and increases restlessness and sleepiness, all symptoms of clinical depression. 3 The presynaptic regulation of serotonin and dopamine transmission, the monoamine transporter molecules 4 on the presynaptic cell surface, are the main site of direct action of modern antidepressants. Monoamine transporter availability can alter the function of postsynaptic receptors, 5 and they are probably needed for recovery from a depressive episode. 6 Polymorphism in serotonin transporter gene is associated with both anxious-related personality traits 7 and major depression. 8, 9 Biochemical imaging techniques enable local measurements of dopamine and serotonin transporters (DAT and SERT, respectively) in the brain to be performed in vivo by using positron emission tomography (PET) or single photon emission tomography (SPET). An iodine-123-labelled cocaine container, 2␤-carbomethoxy-3␤-(4-iodophenyl)tropane, [ 123 I]␤-CIT, has been shown to trace the monoamine, dopamine and serotonin, and, weakly, also noradrenaline, transporter availability in the human brain by SPET. 10, 11 A significant reduction in the availability of hypothalamic/ midbrain serotonin transporters using [ 123 I]␤-CIT has been found in impulsively aggressive 11 and depressive adult alcoholics, 12 and in major depression together with a positive correlation between striatal dopamine and hypothalamic/midbrain serotonin binding ratios. 13 Since prospective studies have shown that depressive episodes in childhood increase the risk of affective illness in adulthood, 14 it is possible that depression in children and adolescents is connected to alterations in the functioning of brain monoamines in the hypothalamus/midbrain and/or in the structure of the cortico-striato-thalamic loop. 15 The purpose of this work is to prove the hypothesis of alterations of serotonin transporter availability in depression in the following regions of interest (ROI):
(1) in the hypothalamus/midbrain area; (2) in the thalamus and in the prefrontal cortex, and dopamine transporter availability in the striatum (the cortico-striatothalamic loop) using the monoamine transporter gamma-camera imaging method in drug-naive children and adolescents.
Materials and methods

Patients
The study was carried out jointly by the Child Psychiatry Clinic and the Division of Nuclear Medicine at the Oulu University Hospital. The protocol was approved by the Ethical Committee of the Oulu University Hospital on February 28, 1996 . The series consisted of 41 drug-naive patients, 14 girls and 20 boys who were being treated at the Child Psychiatry Clinic and seven boys who were residents at an institution for antisocial youngsters. The ages of subjects ranged between 7.7 and 17.4 years, mean 13.2 years. The subjects were offered the opportunity to participate upon receiving permission from their parents. Both the parents and the subjects indicated their informed consent.
All the subjects were free of major somatic medical problems and medication. Misleading results in the transporter imaging were obviated by excluding the drug abusers and those receiving any medication possibly affecting the central nervous system by structured interview, medical records and urine testing. The child psychiatric diagnoses of the subjects were determined through clinical standards in addition to which, a standard diagnostic interview, C-SSAGA, 16 according to DSM-IV criteria, was performed on all the probands. The subjects and their parents and teachers completed the questionnaires (Achenbach) 17 Youth Self-Report Form, Child Behavior Checklist and Teacher's Report Form and the probands also completed the Children's Depression Inventory (Kovacs) . 18 The final diagnoses according to the DSM-IV classification, using all the data mentioned above, were made on a consensus basis by three child psychiatrists (IM, HE, MD), blinded to the imaging results.
Since there were no normal controls available due to the radiation dose involved in SPET imaging, we compared the probands with different symptoms to each other. To study monoamine transporter binding in childhood and adolescent depression we divided the 41 probands into two groups, 31 subjects (mean age 13.5; SD 2.5) suffering from a depressive disorder and 10 subjects (mean age 12.2; SD 2.9) who did not suffer from any depressive disorder during the SPET imaging studies. The depressive group was further split into two groups: major depression present (n = 25, mean age 13.4, SD 2.7) and other depressions present (n = 6, mean age 13.9, SD 1.7). The subjects are described in detail using the consensus diagnoses according to DSM-IV and ICD-10 in Table 1 . 123 I]-CIT was synthesized by a method which has been described in detail previously. 19 After blockade of thyroid uptake with 400 mg potassium perchlorate taken orally 30 min before tracer application, the subjects received a dose of 120-185 MBq [ 123 I]␤-CIT diluted in 10 ml of physiological saline and then slowly injected intravenously.
SPET imaging
SPET studies were performed using a dual head gamma camera (ADAC Vertex) equipped with high resolution fan beam collimators. The subjects head was positioned in a head locker using a crossed laser beam system for repositioning. Raw data were obtained from photopeak counts within a 20% symmetric energy window centered around 159 KeV. A cross-section 4.6-mm thick was reconstructed parallel to the cantomeatal plane by filtered backprojections in a 128 × 128 matrix, using a Butterworth filter (power factor 5, cut-off 0.22 Nq). Attenuation correction was then performed using change zero order correction based on an ellipse fit to the brain with an empirically determined linear attenuation factor (= 0.09 cm
−1
). SPET scans were performed 1, 4 and 24 h after the injection of [ 123 I]␤-CIT. Transaxial slices oriented on the orbito-meatal line were reconstructed and the two slices corresponding to the highest striatal uptake were digitally summed, yielding a final slice 9.2 mm thick (pixel size 4.6 mm, voxel volume 100 mm 3 ). The regions of interest (ROIs) were drawn over the right and left striatum (STR, 24 px), over the prefrontal cortex (PF 15 px), the thalamus (Th, 11 px) and over the hypothalamus and midbrain, including the raphe nuclei, substantia nigra and the colliculi (HMB, 9 px). 20 These areas were identified by reference to Talairach Stereotactic Atlas and MRI scans (exceptionally performed in three patients). Hypothalamic/midbrain area of activity was consistently detected in the midline, about 12 mm below the level of striatal transversal slice (Figure 1 ). Occipital white matter ROI, (OWM) was drawn in the level of the striatum, and taken as the reference area (non-displaceable uptake), since post-mortem studies have shown a very low density of both dopamine and serotonin transporters in this region. 21 The technician performing the analysis of the ROIs was unaware of the demographics and the diagnosis of the subjects. The ratio STR-OWM/OWM = specific/non-displaceable activity at 24 h after the injection was used for semiquantification of the dopamine transporters. 22 This ratio can be used as an estimate of binding potential since the state of equilibrium has been documented to exist in the striatal and occipital areas at 24 h after the injection. Based on the findings of serotonin transporter binding kinetics, 21, [23] [24] [25] [26] the following ratios at 1, 4 and 24 h after the injection were used for semiquantification of the serotonin transporters: HMB/OWM, Th/OWM and PF/OWM, the optimal imaging time in hypothalamic/midbrain area being 1 h, and in thalamus 4 h after the injection. 25, 26 
Statistical methods
The results in terms of hypothalamic/midbrain area 1-h binding ratios were presented in dot plots. The significances of the differences between the groups were tested using Mann-Whitney's U-test. Correlations with age were calculated using Pearson's correlation coefficient. Stepwise linear regression (SPSS) was performed to test which factors significantly influenced the change in SERT binding in the hypothalamic/ midbrain area.
Results
Figure 2 demonstrates the [
123 I]␤-CIT uptake, consisting mainly of serotonin transporters (SERT), in the hypothalamic/midbrain area (HMB), 1, 4 and 24 h after the injection of the tracer. At 1 h in HMB, the depressive subjects (n = 31, 22 boys, 9 girls) presented higher SERT binding ratios 1.28 ± 0.11 (mean ± SD) than the non-depressive subjects (n = 10, 5 boys, 5 girls), 1.18 ± 0.12, and the difference was statistically significant (P = 0.02). The dot plots are shown in Figure 3 . The results were not affected by the gender of the subjects. The depressive boys (n = 22) showed higher binding ratio 1.28 ± 0.12 than the non-depressive boys (n = 5) 1.18 ± 0.17 (P = 0.14) and the depressive girls (n = 9) showed a higher binding ratio 1.29 ± 0.08 than the nondepressive girls (n = 5) 1.19 ± 0.12 (P = 0.06). When either the depressive boys or girls or the non-depressive boys or girls were compared, the differences were not significant (P = 0.66, P = 0.83). The SERT binding ratios in the hypothalamic/midbrain area at 1 h did not correlate to the ages of the subjects (Figure 4) . At 4 h, the SERT binding ratio in HMB was 1.57 ± 0.20 (mean Molecular Psychiatry ± SD) in the depressives and 1.44 ± 0.12 in the nondepressives (P = 0.08). At 24 h, the SERT binding ratios in HMB were 2.27 ± 0.33 (mean ± SD) in the depressives and 1.86 ± 0.23 in the non-depressives (P = 0.04). There were no significant differences between the series in [ 123 I]␤-CIT uptake in the thalamic or prefrontal ROIs for SERT.
Study of the two subgroups of depressive patients separately, those with major depression present (n = 25) and those with other depressive disorders present (n = 6), compared with the non-depressive patients (n = 10), revealed major differences only between both depressives and non-depressives. The SERT binding ratios in the hypothalamic/midbrain area at 1 h were 1.28 ± 0.11 (mean ± SD) for the subjects with major depression, 1.30 ± 0.10 for the subjects with other depressions (P = 0.60) and for the subjects without depression 1.18 ± 0.14. The differences between the non-depressive subjects and both those with major depression and those with other depression were significant (P = 0.04). The dot plots are shown in Figure 5 .
The same comparisons in the 24-h imaging revealed no significant differences between the two depressive groups, or between the other depressives and the nondepressives. The SERT binding ratio was higher in the major depressive patients 2.15 ± 0.38 (mean ± SD) than in the non-depressive patients, 1.89 ± 0.34 (P = 0.05).
Stepwise linear regression showed that only the presence of the depressions (P = 0.03) was a significant predictor of change in the SERT binding ratio in the hypothalamic/midbrain area at 1 h, but age, gender or co-morbid conduct disorder or any other comorbidities were not.
The dopamine transporter (DAT) binding ratios at 
Figure 3
Scatter plots of SERT-binding ratios in the hypothalamic/midbrain area at 1 h were (mean ± SD) 1.28 ± 0.11 (n = 31) in the depressive patients and 1.18 ± 0.12 (n = 10) in the non-depressive patients. The difference was statistically significant (P = 0.02).
24 h in the striatum were 9.15 ± 1.25 (mean ± SD) in the depressive patients and 9.11 ± 1.24 in the non-depressives. The difference was not significant (P = 0.89). The hypothalamic/midbrain SERT binding ratios at 1 h and 4 h did not correlate to the striatal DAT binding. At 24 h, a statistically significant correlation between hypothalamic/midbrain SERT and striatal DAT binding ratios was detected (r = 0.43, P = 0.006). The scatter plots of SERT-binding ratios in the hypothalamic/midbrain area at 1 h in the subjects with major depression (mean ± SD) were 1.28 ± 0.11 and in the subjects with other depression 1.33 ± 0.10. The difference was not significant (P = 0.60). The scatter plots of SERT-binding ratios in the hypothalamic/midbrain area at 1 h in the subjects without depression were correspondingly 1.18 ± 0.14. The difference was significant both to the major depression (P = 0.04) and to the other depressions (P = 0.04).
Discussion
Monoamines in depression
This is the first study to provide data of significant differences in serotonin transporter availability in the brain of depressive children and adolescent patients compared to that of non-depressive patients. Extensive research has shown a correlation between reduced brain serotonin functioning and depressive, aggressive, impulsive and anxious models of behavior. Studies of adults have pointed to diminished serotonin availability as a possible explanation of depression in humans: a diminished cerebral fluid concentration of 5-hydroxy-indole-acetate-acid (5-HIAA), the main metabolite of serotonin, 27 low platelet serotonin concentrations, 28 and diminished concentrations of serotonin precursor tryptophan in plasma, 29 diminished prolactin rise induced by the serotonin releasing agent fenfluramine 30 and by the serotonergic precursor 5-hydroxy-L-tryptophan (L-5-HTP), 31 and reduced [ 123 I]␤-CIT uptake in brainstem 13 occurs in depressive patients. Post mortem studies of the brains of the adult depressives and the suicide victims showed changes in both serotonin transporter 32 and in serotonin receptor density [33] [34] [35] in prefrontal cortex, and an increase in serotonin uptake in midbrain. 36 However, non suicidal depressive adults did not present changes in serotonin receptor binding in prefrontal cortex. 37 Specific SSRIagents are effective in the treatment of both depressive adults 38 and depressive adolescents. 39 Altered serotonergic function has been noted in depressive children, too. In contrast to studies of adults, prepubertal children with major depression had augmented prolactin responses to the serotonin precursor L-5-HTP. 40 This finding has been true also for the siblings and the children of the depressed patients, and thought to mark a possible biological antecedent of the depression. 41 
Molecular Psychiatry
Our findings point to elevated SERT availability in the hypothalamic/midbrain area, not to diminished SERT availability as in the depressive adults.
Dopamine is associated mostly with the promotion of attention and learning highlighting stimuli 42 but also with mediating highs-pleasure and excitement-in direct proportion to the transporter blocking in cocaine abuse. 43 In mood disorders, dopamine is involved in the mobilization, facilitation and sustenance of goaldirected behaviour. 1, 44 The dopamine-active antidepressants, roxindole and sulpiride, have a more rapid course of action than tricyclic and SSRI drugs, both of which in their turn enhance dopaminergic neurotransmission within 3 weeks of commencement. 45 In fact, results from studies in depression, Parkinson's disease and animal models of depression suggest deficiency of dopamine as the model of depression has a very high probability. 46 Depressive symptoms have previously correlated inversely to dopamine transporter availability in alcoholics. 47 There are no previous studies on brain dopamine activity in depressive children, but dopamine-active drugs have a well proven, serotonin-mediated effect on the symptoms of attention deficit hyperactivity disorder. 48 In this study, we found no significant difference in the striatal DAT binding between depressive and non-depressive child psychiatric patients. However, binding of the ligand in the hypothalamic/midbrain area, at 24 h representing mainly SERT, contains to some extent DAT binding as well. 21, 49 The dopaminergic neurons in the ventral tegmental area (VTA) and in substantia nigra and the serotoninergic neurons in nucleus raphe are summated visually in the hypothalamic/midbrain area. An earlier in vitro estimate of DAT binding in substantia nigra is 0.3 vs 1.0 of SERT binding. 49 The role of norepinephrine in depression is controversial. Tricyclic antidepressant treatment enhances both ␣-adrenergic and serotoninergic function in the brain, but depression and serotonin deficiency may also be connected with and initiated by increased ␤-adrenergic activity in the brain. 5 ␤-CIT and monoamine transporter availability [ 123 I]␤-CIT is well established for tracing dopamine transporters in striatum. 50 Recent studies have shown that [ 123 I]␤-CIT labels the serotonin-rich areas of the prefrontal cortex, the hypothalamus/midbrain and the thalamus. 49, 51 The serotonin and dopamine re-uptake sites can be differentiated by simultaneous treatment with citalopram. 21, 23 In the hypothalamic/midbrain area, including raphe nuclei, ventral tegmental area, substantia nigra and the colliculi containing mainly serotonin transporters, [ 123 I]␤-CIT uptake reaches its highest value at 1-2 h after the injection. Thalamic activity (serotonin transporters) peaks at 4 h after the injection 24, 25 correspondingly. Since previous studies have not revealed significant changes in blood flow either in the hypothalamus/midbrain area or in the thalamus in depressive states 52 53 The equilibrium state of dopamine transporters in the striatum is reached 16-20 h after the injection. 25, 26 In accordance with [
123 I]␤-CIT kinetic studies, 21, [23] [24] [25] [26] we found statistically significant results in the depressive children at the optimal imaging time (1-2 h) for the SERT binding in the hypothalamic/midbrain area. Areas visualized in the hypothalamic/midbrain ROI, such as substantia nigra and ventral tegmental area are rich in dopamine cell bodies, and it is likely that some of the [ 123 I]␤-CIT signal at 24 h arises from DAT-binding. 21 Interestingly, we did find a significant correlation (P = 0.006) between ␤-CIT-binding in striatum and in hypothalamus/midbrain at 24 h, supporting the previous statement.
Elevated serotonin transporter availability may be due to: (1) decreased serotonin concentrations in the synapse thus allowing [
123 I]␤-CIT to bind into the transporters; 49 (2) increased number of synapses; or (3) elevated transporter density or affinity 54 in the serotonergic neurons in the midbrain/hypothalamus area. Since serotonin turnover is believed to be decreased in depression, 55, 56 it is likely that the elevation of [ 123 I]␤-CIT uptake in the hypothalamic/midbrain area is due to decreased serotonin concentrations in the synapse. In rhesus monkeys, depletion of serotonin was induced with p-clorophenylalanine and resulted in a significant increase in [ 123 I]␤-CIT binding to serotonin transporters, confirming the hypothesis that there is competition between endogenous serotonin and in vivo radioligand binding. 57 Significant negative correlation between [ 123 I]␤-CIT uptake in brain-stem and CSF 5-HIIA concentrations has been shown in non-human primates 58 as well as in human alcoholics and controls. 57 The few measures of depressed children have shown that augmented serotonin precursor induced a prolactin rise rather than blunted it, findings opposite to those of adults. 40, 41 This finding may be, however, confounded by the differences in serotonin-induced prolactin secretion between prepuberty and adulthood. In this study no significant differences occurred during the transition from childhood into puberty in either of the groups. There are no studies on gender differences in SERT binding in the depressive or in the nondepressive adults.
The difference in transporter binding between depressive adults, and children and adolescents, could also be developmental. In early life transporter molecules could be more active or there could be more synapses in the serotonergic neurons but later in the course of depression, the amount of either transporter molecules, or the synapses, or the both, would simply decline as a compensatory event for the chronic deficit of the synaptic serotonin-a habituation process into the continuity of the depressive episodes. Therefore decreased SERT availability would be present only in adults. In addition, the availability of serotonin transporters in adult depressives can be diminished due to chronic drug (antidepressive) exposure.
11-13
Depression in children and adolescents Depressive episodes in children and adolescents consist of lowered mood or irritability and often cooccur with conduct problems. 59 Co-morbid conduct disorder, however did not significantly influence the change in serotonin transporter binding ratios in the hypothalamic/midbrain area (stepwise linear regression). In this study the patients with other depression (Table 1) are grouped together with those with major depression since many children and adolescents do not possess the developmental maturity required for insight and verbal report of one's depressive symptoms. 60 The hypothalamic/midbrain SERT binding ratios in these two depressive groups did not differ significantly ( Figure 5 ). Epidemiologically too, symptoms of depression as well as major depression in adolescence predict vulnerability to major depression later in life. 61 These findings suggest that major depression and the other depressions would present a common biochemical background.
The most definitive conclusions could be made with healthy controls, which are, for ethical reasons not to be used in isotope studies of children and adolescents. Those patients having conditions other than depressive disorders, make up the only possible, reliable comparison group, since the co-morbidities are similar in both groups. Since the normal controls are not available it is possible to interpret the results to indicate a decrease in SERT, and eventually in DAT, availability in the non-depressive psychiatric control group. According to the linear regression analysis, however, only the presence of depression, not any of the comorbidities, significantly affected the change in SERT binding in the hypothalamic/midbrain area at both 1 and 24 h. Therefore we interpret our results to indicate the elevation in SERT availability in depression. The small number of subjects does not allow age and gender-matched comparison, which remains to be done in the future.
Conclusion
Our findings in depressive children and adolescents suggest significant increase in serotonin transporter availability in hypothalamus/midbrain area, at the optimal imaging time (1 h after introduction of the radiolabelled ligand). No difference was found in striatal dopamine transporter availability, but the elevated binding of the ligand at 24 h in hypothalamus/ midbrain most probably represents both dopamine and serotonin binding. Thus, the serotonin transporter binding in depressive children and adolescents seems to differ from that of adults. 13 Replication of our initial findings in future neuroimaging studies of genotyped depressives, using recently developed more selective PET or SPET tracers, for both pre-and postsynaptic receptors, together with serotonin turnover measurements, will be critical to obtain a more comprehensive view of serotonin functioning in depressive children and adolescents.
